Key facts
- Metabolon’s last known valuation is $187.3M (Aug 2018).
- It has raised $345.9M across 8 recorded rounds; the latest was Early Stage VC ($7.5M) in Dec 2024.
- Notable investors include Perceptive Advisors, Revelation Partners, Syngenta Group Ventures, Camden Partners, Fulcrum Financial Partners — 10 tracked in total.
- Metabolon has filed 14 Form Ds with the SEC since 2009, most recently Jan 2025 ($7.5M sold to 11 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 8 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Metabolon
Funding rounds
8 roundsAbout Metabolon
Developer of metabolomic profiling technologies designed for biochemical data interpretation and to transform complex biological data discoveries. The company's technologies integrate proprietary reference libraries, high-throughput analytical techniques, and bioinformatics tools to deliver annotated metabolite data, pathway mapping, and translational insights, enabling life sciences researchers and pharmaceutical developers to uncover biological mechanisms, accelerate discovery, enhance clinical development, and complement other omics approaches with precise molecular context and scalable data outputs.
- Sector
- Healthcare
- HQ
- Morrisville, NC, United States
- Founded
- 2000
- Employees
- 278
- Website
- metabolon.com/
- Ownership
- Privately Held (backing)
Metabolon doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Metabolon shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Metabolon in its N-PORT filings yet. We sweep new filings monthly.